gemtuzumab ozogamicin

Ligand id: 6775

Name: gemtuzumab ozogamicin

No information available.
Summary of Clinical Use
Used to treat CD33-positive acute myeloid leukemia (AML) in patients over 60 who are not candidates for other chemotherapy. Note that as requested by the US FDA, the drug was withdrawn from the US market in 2010, due to questions over its effectiveness and safety. Other international regulatory authorities still approve use of this drug.

In September 2017, after careful reveiw, the FDA approved gemtuzumab ozogamicin for two new uses:
1. Initial use in adults whose AML tumors express the CD33 antigen.
2. For patients aged ≥2 years with relapsed or refractory CD33-positive AML.
Mechanism Of Action and Pharmacodynamic Effects
Antineoplastic conjugate of anti-CD33 antibody and the cytotoxic antibiotic calicheamicin γ1. The conjugate binds to the cell surface receptor and is rapidly internalised, subsequently the calicheamicin γ1 binds to the minor groove of DNA molecules and causes DNA double-strand breaks which triggers apoptosis.